• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of nephrology. >Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration
【24h】

Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration

机译：尿卷作为血液渗透患者连续输注过程中呋塞米静脉紊乱的预测因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundThis study assessed the contribution of intracorporeal (IC) and extracorporeal clearance (EC) of furosemide in patients with septic acute kidney injury (AKI), and the relationship between plasma concentrations and urine volume.MethodsProspective cohort observational study of 15 patients with septic AKI undergoing continuous veno-venous hemodiafiltration (CVVHDF) divided according to urine volume (500ml/12h, Oliguria group, n=5; 500ml/12h, Diuresis group, n=10) during continuous infusion of furosemide (120mg/12h) at steady-state condition. Plasma and effluent furosemide concentrations were determined by high-performance liquid chromatography (HPLC)-mass spectrometry every 12h for 48h.ResultsFurosemide plasma concentrations and total body clearance (TBC) were 6.14mg/l and 22.1ml/min for the Oliguria group, and 2.63mg/l and 54.4ml/min for the Diuresis group, respectively (p0.05). When urine volume was 500ml/24h, the furosemide plasma concentrations peaked at the potentially toxic value of 13.0mg/l. Furosemide EC was not relevant for the Diuresis group, but it represented 18% of TBC for the Oliguria group. Furosemide plasma concentrations correlated positively with dose infusion for both groups (r = 0.728 and 0.685, p0.05), and negatively with urine volume only for the Diuresis (r = - 0.578, p0.01) but not for the Oliguria group (r = - 0.089, p = 0.715).ConclusionsFor patients with urine volume500ml/12h continuous infusion of furosemide up to 480mg/24h leads to increasing urine volume, which can predict furosemide plasma levels within its safety range. When the urine volume is lower, the furosemide plasma levels are increased beyond any further diuretic efficacy.
机译：背景研究评估了呋塞米患者体内（IC）和体外清除（EC）脓毒症急性肾损伤（AKI）的贡献，以及血浆浓度与尿量之间的关系。普遍存在症的普遍症患者患者的血浆竞争性群体观察研究连续静脉血管血氧（CVVHDF）根据尿量（＆lt，500ml / 12h，寡核碱组，N = 5;＆ 500ml / 12h，Diulesis组，N = 10）分开在连续输注呋塞米（120mg / 12h）期间处于稳态状态。通过高效液相色谱法（HPLC）--mass光谱法测定等离子体和污水呋塞米浓度，每12小时测定48小时。核苷酸血浆血浆浓度和总体间隙（TBC）为寡尿组织为6.14mg / L和22.1mL / min分别为54.3mg / L和54.4ml / min（P <0.05）。当尿体积为<500ml / 24h时，呋塞米血浆浓度在潜在有毒值为13.0mg /升时达到峰值。 Furosemide EC与Diuseis组无关，但它代表了寡尿组的18％的TBC。呋塞米血浆浓度与两组的剂量输注相关（r = 0.728和0.685，p <0.05），并且仅对Diuresis（r = - 0.578，p <0.01）负面呈尿量，但不适用于寡尿组（R. = - 0.089，p = 0.715）。对于尿量患者，尿量患者，500ml / 12h连续输注呋塞米高达480mg / 24h，导致尿量增加，这可以预测其安全范围内的呋塞米等离子体水平。当尿量较低时，呋塞米等离子体水平增加超过任何进一步的利尿功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号